Therapeutic potential of peroxisome proliferators-activated receptor-α/γ dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes

Diabetes

Volumn 57, Issue 3, 2008, Pages 737-745

  Han, Kyu Lee ^a,b   Choi, Joo Sun ^b   Lee, Jae Young ^a   Song, Jihyun ^b   Joe, Myung Kuk ^b   Jung, Myeong Ho ^b,c,d   Hwang, Jae Kwan ^a  

^a Yonsei University   (South Korea)

^b Korea National Institute of Health   (South Korea)

^c Pusan National University   (South Korea)

^d School of Korean Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A OXIDASE; ADIPONECTIN; BETA ACTIN; CARNITINE PALMITOYLTRANSFERASE I; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD36 ANTIGEN; FATTY ACID; FATTY ACID SYNTHASE; GLUCOSE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; LIPOPROTEIN LIPASE; MACELIGNAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHOTRANSFERASE; PIRINIXIC ACID; PYRUVATE DEHYDROGENASE KINASE 4; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR GAL4; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 3; UNINDEXED DRUG; INSULIN RECEPTOR SUBSTRATE 1 PROTEIN; INSULIN RECEPTOR SUBSTRATE-1 PROTEIN; LIGNAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; THAPSIGARGIN;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FATTY ACID BLOOD LEVEL; GENE EXPRESSION REGULATION; GENE TARGETING; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; ENDOPLASMIC RETICULUM; LIVER; METABOLISM; MOUSE MUTANT; NUTMEG; STRESS; WHITE ADIPOSE TISSUE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADIPOSE TISSUE, WHITE; ANIMALS; CELL LINE; DIABETES MELLITUS, TYPE 2; ENDOPLASMIC RETICULUM; LIGNANS; LIVER; MICE; MICE, OBESE; MOLECULAR STRUCTURE; MYRISTICA FRAGRANS; PPAR ALPHA; PPAR GAMMA; STRESS; THAPSIGARGIN;

EID: 40949093618     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-0972     Document Type: Article

References (25)

1. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 53:409-352, 2002
2. Willson TM, Lambert MH, Kliewer SA: Peroxisome proliferator-activated receptor γ and metabolic disease. Annu Rev Biochem 70:341-367, 2001
3. Cignarella A, Bellosta S, Corsini A, Bolego C: Hypolipidemic therapy for the metabolic syndrome. Pharmacol Res 53:492-500, 2006
4. Ferre P: The biology of peroxisome proliferators-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (Suppl. 1):S43-S50, 2004
5. Henke BR: Peroxisome proliferators-activated receptor α/γdual agonists for the treatment of type 2 diabetes. J Med Chem 47:4118-4127, 2004
6. Staels B, Fruchart JC: Therapeutic roles of peroxisome proliferators-activated receptor agonists. Diabetes 54:2460-2470, 2005
7. Wang HX, Ng TB: Natural products with hypoglycemic, hypotensive, hypocholesterolemic, antiatherosclerotic and antithrombotic activities. Life Sci 65:2663-2677, 1999
8. Olajide OA, Ajayi FF, Ekhelar AI, Awe SO, Makinde JM, Alada AR: Biological effects of Myristica fragrans (nutmeg) extract. Phytother Res 13:344-345, 1999
9. Ram A, Lauria P, Gupta R, Sharma VN: Hypolipidaemic effect of Myristica fragrans fruit extract in rabbits. J Ethnopharmacol 55:49-53, 1996
10. 10.Hussain SP, Rao AR: Chemopreventive action of mace (Myristica fragrans, Houtt) on methylcholanthrene-induced carcinogenesis in the uterine cervix in mice. Cancer Lett 56:231-234, 1991
11. Chung JY, Choo JH, Lee MH, Hwang JK: Anticariogenic activity of macelignan isolated from Myristica fragrans (nutmeg) against Streptococcus mutans. Phytomedicine 13:261-266, 2006
12. Choi BH, Ahn IS, Kim YH, Park JW, Lee SY, Hyun CK, Do MS: Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol Med 38:599-605, 2006
13. Han KL, Jung MH, Sohn JH, Hwang JK: Ginsenoside 20(S)-protopanaxat-riol (PPT) activates peroxisome proliferators-activated receptor γ in 3T3-L1 adipocytes. Biol Pham Bull 29:110-113, 2006
14. Murase T, Aoki M, Tokimitsu I: Supplementation with alpha-linolenic acid-rich diacylglycerol suppresses fatty liver formation accompanied by an up-regulation of beta-oxidation in Zucker fatty rats. Biochim Biophys Acta 1733:224-231, 2005
15. Skrumsager BK, Nielsen KK, Muller M, Pabst G, Drake PG, Edsberg B: Ragaglitazar: the pharmacokinetics, pharmacodynamics and tolerability of a novel dual PPARα/γagonist in healthy subjects and patients with type2 diabetes. J Clin Pharmacol 43:1244-1256, 2003
16. Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H, Stender S, Stoa-Birketvedt G, Tonstad S, Halldorsdottir S, Gause-Nilsson I: Tesagli- tazar, a novel dual peroxisome proliferator-activated receptor α/γagonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48:1716-1725, 2005
17. Harrity T, Farrelly D, Tieman A, Chu CL, Gu L, Ponticiello R, Cap M, Qu F, Shao C, Wang W, Zhang H, Fenderson W, Chen S, Devasthale P, Jeon Y, Seethala R, Yang WP, Ren J, Zhou M, Ryono D, Biller S, Mookhtiar KA, Wetterau J, Gregg R, Cheng PT, Hariharan N: Muraglitazar, a novel dual (α/γ)peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves β-cell function in db/db mice. Diabetes 55:240-248, 2006
18. Koyama H, Miller DJ, Boueres JK, Desai RC, Jones AB, Berger JP, MacNaul KL, Kelly LJ, Doebber TW, Wu MS, Zhou G, Wang PR, Ippolito MC, Chao YS, Agrawal AK, Franklin R, Heck JV, Wright SD, Moller DE, Sahoo SP: (2r)-2-ethylchromane-2- carboxylic acids: discovery of novel PPARalpha/ gamma dual agonists as antmyperglycemic and hypolipidemic agents. J Med Chem 47:3255-3263, 2004
19. Fievet C, Fruchart JC, Staels B: PPARα and pparγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr Opin Pharmacol 6:606-614, 2006
20. Jin DQ, Lim CS, Hwang JK, Han JS: Anti-oxidant and anti-inflammatory activities of macelignan in murine hippocampal cell line and primary culture of rat microglial cells. Biochem Biophys Res Commun 331:1264- 1269, 2005
21. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293:1673-1677, 2001
22. Long YC, Zierath JR: AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 116:1776-1783, 2006
23. Muoio DM, Newgard CB: Biomedicine, Insulin resistance takes a trip through the ER. Science 306:452-456, 2004
24. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoslii NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, Hotamisliqil GS: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457-461, 2004
25. Marx J: Cell biology: a stressful situation. Science 313:1564-1566, 2006